NCT00143312 - Voriconazole for Secondary Prophylaxis of Invasive Fungal Infections in Patients With Allogeneic Stem Cell Transplants | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2005

Primary Completion Date

April 30, 2008

Study Completion Date

April 30, 2008

Conditions

Prophylaxis Of Invasive Fungal Infections

Interventions

DRUG

voriconazole

Voriconazole is given to patients at least 48 hours after chemotherapy

Trial Locations (17)

3000

Pfizer Investigational Site, Leuven

13273

Pfizer Investigational Site, Marseille

28006

Pfizer Investigational Site, Madrid

33600

Pfizer Investigational Site, Pessac

50937

Pfizer Investigational Site, Cologne

55101

Pfizer Investigational Site, Mainz

67098

Pfizer Investigational Site, Strasbourg

94010

Pfizer Investigational Site, Créteil

97070

Pfizer Investigational Site, Würzburg

44035 cedex

Pfizer Investigational Site, Nantes

1099-023

Pfizer Investigational Site, Lisbon

08025

Pfizer Investigational Site, Barcelona

08036

Pfizer Investigational Site, Barcelona

141 86

Pfizer Investigational Site, Stockholm

Unknown

Pfizer Investigational Site, Ch-4031 Basel

W12 0NN

Pfizer Investigational Site, London

M20 4BX

Pfizer Investigational Site, Manchester